Table 1. Baseline characteristics of participants.
| DEMOGRAPHIC CHARACTERISTICS | N (%)* |
|---|---|
| Total No. Patients | 153 |
| Women1 | 87 (57%) |
| Median age at baseline2 in years (IQR) | 39 (33–45) |
| HIV transmission risk category3 | |
| Heterosexual | 138 (90%) |
| MSM | 7 (5%) |
| Other (work exposure, blood transfusion, unknown) | 9 (6%) |
| HIV DISEASE PARAMETERS | |
| Median duration of HIV in years at baseline2 (IQR) | 3 (0–7) |
| Baseline2 CD4 <200 cells/μL (of 145 available) | 66 (46%) |
| Median baseline2 CD4 (cells/μL) (IQR) | 211 (135–265) |
| Baseline2 VL <1000 copies/mL (of 58 available) | 4 (7%) |
| Median baseline2 VL (copies/mL) (IQR) | 74,241 (18,784–178,5804) |
| Initiated ART with PI-based regimen | 5 (3%) |
| Initiated ART with NNRTI-based regimen | 148 (97%) |
| CARDIOVASCULAR RISK FACTORS | |
| Median baseline BMI4 (kg/m2) (IQR) | 24.5 (22–28) |
| Hypertension5 | 30(20%) |
| Lipid lowering medication use | 22 (14%) |
| Current smoker | 21 (14%) |
| OTHER RELEVANT CLINICAL CHARACTERISTICS | |
| Depressive symptoms during observation period | 126 (82%) |
| Current drug use (heroin, crack/cocaine, marijuana, or ecstasy) | 9 (6%) |
| Average # drinks consumed per month throughout observation period | |
| 0 | 58 (38%) |
| 1–10 | 81 (53%) |
| ≥11 | 14 (9%) |
* Percent unless otherwise specified
1 No patients identified as transgender in this cohort
2Baseline measures taken ≤180 days prior to ART initiation
3 No patients reported transmission risk factors of intravenous drug use or vertical transmission
4Body mass index, baseline measures taken ≤180 days prior to ART initiation or ≥30 days after ART initiation
5 Hypertension was defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90